Medical/Pharmaceuticals

Rapid acceleration of medical education for Japan's medical students using VR - NHK special feature published online

TOKYO, Sept. 2, 2021 /PRNewswire/ -- At many Japanese institutions offering medical education, medical students are unable to attend clinical practice due to the spread of COVID-19, denying them the experience of valuable opportunities to learn. Efforts by Jolly Good and Nippon Medical School to...

2021-09-02 21:00 2459

I-Mab Added to FTSE Russell Global Equity Index Series

SHANGHAI and GAITHERSBURG, Md., Sept. 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE Global Eq...

2021-09-02 20:00 6450

EmitBio Results Yield 99.99% Reduction of Delta in Human Tissue

New data proves technology neutralizes the Delta variant Third Human Trial Underway DURHAM, N.C., Sept. 1, 2021 /PRNewswire/ -- EmitBio, Inc., a life science company, today announced successful results from a new In Vitro Neutralization study of the Delta variant in human airway tissue. The stud...

2021-09-01 21:00 2409

Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 1, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) appl...

2021-09-01 13:05 3065

Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed

TAIPEI and SAN DIEGO, Aug. 31, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that its oral new drug, Silmitasertib, had received a positive feedbac...

2021-08-31 19:00 1930

Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial

* Topical treatment safe and well tolerated in study of healthy volunteers * Full inhibition of lysyl oxidase enzymes achieved in skin with minimal systemic exposure * Collaboration with research team led by Professor Fiona Wood AM planning for trial in patients with established scars to com...

2021-08-31 18:00 1794

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021

* 13 significant clinical milestones achieved year-to-date, including critical positive data readout events for felzartamab (TJ202/MOR202), lemzoparlimab (TJC4), uliledlimab (TJD5), and plonmarlimab (TJM2) and more milestone achievements are expected before the year-end 2021 * Felzartamab (TJ...

2021-08-31 18:00 3758

Harbour BioMed Reports 2021 Interim Results

CAMBRIDGE, Mass.and SUZHOU, China and ROTTERDAM, Netherlands, Aug. 31, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, reported its interim...

2021-08-31 13:47 4043

InnoCare Announces Clearance by U.S. FDA of Clinical Trial of pan-TRK Inhibitor ICP-723

BEIJING, Aug. 30, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biopharmaceutical company, announced today the Investigational New Drug (IND) clearance of its second-generation pan-TRK inhibitor ICP-723 by the US Food and Drug Administration (FDA) for starting phase I cli...

2021-08-31 08:30 2808

Through CEO of Hanmi Science, CancerRop Issues KRW 20 Billion New Shares for Cooperation with Oxford Vacmedix

SEOUL, South Korea, Aug. 30, 2021 /PRNewswire/ -- CancerRop (180400), a company specializing in precision medicine and molecular diagnostics, announced a jump start in the global vaccine hub for COVID-19 mRNA (messenger ribonucleic acid) with Hanmi Science through20 billion won worth of investmen...

2021-08-30 23:00 3556

I-Mab Announces Upcoming Participation at September Conferences

SHANGHAI and GAITHERSBURG, Md., Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in Septem...

2021-08-30 20:00 2025

GeneQuantum announces Dr. Yi Xia as Senior Vice President of Statistics and Data Science

SUZHOU, China, Aug. 29, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmaceutical company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announces the appointment of Dr.Yi Xia as Seni...

2021-08-30 10:00 2275

InnoCare Releases 2021 Half Year Results and Business Highlights

BEIJING, Aug. 29, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 half year results which ended onJune 30, 2021. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "On the fo...

2021-08-29 19:49 5008

IONOVA Life Science Announces New Financing Round of USD $100 Million

SHENZHEN, China, Aug. 27, 2021 /PRNewswire/ -- On August 27, 2021, Shenzhen IONOVA Life Science Co., Ltd. ("IONOVA" or "the company"), a clinical-stage biotechnology company located in theGuangdong-Hong Kong-Macao Greater Bay Area ofChina, announced completion of a new financing round of USD $100...

2021-08-27 22:00 3226

Bunshi Lab Starts Accepting Pre-orders for "Bunshi Mask" -- Best-selling Crowdfunded Face Mask in Japan -- through "Indiegogo" Crowdfunding Website

FUKUOKA, Japan, Aug. 27, 2021 /PRNewswire/ -- Bunshi Lab ("bunshi" meaning molecule in Japanese) has raised approximately180 million yen (*1) for the "Bunshi Mask" through "Makuake," a Japanese crowdfunding website. Now, Bunshi Lab is launching a much-awaited global sales campaign for the product...

2021-08-27 16:00 1498

Laekna Therapeutics Receives IND Approvals in China and US for Phase Ib/III Global Multi-center Clinical Study of Afuresertib in combination with fulvestrant for patients with HR+/HER2- breast cancer

SHANGHAI and WAREN, New Jersey, Aug. 26, 2021 /PRNewswire/ -- Laekna Therapeutics announced today that the Center for Drug Evaluation (CDE), the National Medical Products Administration (NMPA) ofChina has approved the Investigational New Drug (IND) application of its Category 1 new drug candidate...

2021-08-27 11:20 1811

PharmaBlock Announces the Appointment of Dr. Xudong Wei as Senior Vice President to Lead and Enhance Small Molecule CDMO Services

NANJING, China, Aug. 26, 2021 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr.Xudong Wei as Senior Vice President and Head of CDMO Business to enhance s...

2021-08-26 23:00 4029

3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development

HONG KONG, Aug. 26, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2021 interim results. 3SBio maintained strong performance in core businesses, with core products occupying a leading market share. Meanwhile, the Company continuously increased ...

2021-08-26 22:09 6244

Aqueous Ozone by BES Group Proves Effective in Killing COVID-19

SAN ANTONIO, Aug. 25, 2021 /PRNewswire/ -- Aqueous ozone by BES Group's Multi-Purpose Ozone Bottle and Professional Ozone Spray Bottle has proved effective in killing SARS-CoV-2, the virus that causes COVID-19 in testing by a third-party lab at Nara Medical University inJapan.

2021-08-25 22:00 3323

First patient treated in Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial

SYDNEY, Aug. 25, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or the "Company"), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that the first US patient has ...

2021-08-25 21:18 6291
1 ... 225226227228229230231 ... 250